Loading clinical trials...

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

A Feasibility Study for a Phase 3, Randomized, Four-Week, Double-Blind, Placebo-Controlled, Crossover Trial of the Efficacy and Safety of PH94B Nasal Spray in the Acute Treatment of Social Anxiety Disorder (SAD)

NCT02622958•Pherin Pharmaceuticals, Inc.

View on ClinicalTrials.gov

Summary

The purpose of the study is to determine whether the PH94B nasal spray is effective for Acute Treatment of the symptoms of Social Anxiety Disorder (SAD) in adult men and women. The hypothesis is that PH94B nasal spray (.8 micrograms) has a rapid onset of efficacy to improve performance and interaction anxiety in patients with diagnosed Social Anxiety Disorder (SAD).

Detailed Description

The study is a randomized, double-blind, placebo-controlled, 2-way crossover trial of the efficacy and safety of PH94B in the treatment of subjects diagnosed with Social Anxiety Disorder as defined by the Diagnostic and Statistical Manual IV and confirmed by the MINI (5.0.0). The study is intended to serve as a feasibility trial of a multi-center phase 3 study protocol of similar design. The primary objective of this study is to evaluate design features for a larger Phase 3 study that will evaluate the safety and efficacy of PH94B for the acute management of symptoms in subjects with Social Anxiety Disorder. Careful review of diary entries and measurement of study medication compliance each week will be used to determine the feasibility of using the study medication on an "as needed" basis for anxiety-provoking social events. Specifically, the frequency of use, variability of SUDS ratings, effect size of differences in average peak SUDS ratings during treatment with PH94B and placebo, and general reliability of the diary recording method will be evaluated and used to refine inclusion and exclusion criteria as well as provide guidance for designing a larger multi-site study. The study will last a total of 6-8 weeks. The randomized double-blind treatment period will last a total of four weeks for all subjects.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Written informed consent provided prior to conducting any study-specific assessment.
•Male and female adults, 18 through 65 years of age, inclusive.
•Current diagnosis of Social Anxiety Disorder as defined in the DSM IV of Mental Disorders, which is not secondary to another pre-existing psychiatric condition or to a medical condition.
•Confirmation of diagnosis of Social Anxiety Disorder according to the MINI, 5.0.0
•Clinician-rated Liebowitz Social Anxiety Scale total score ≥60 at both Screening and Baseline visits.
•Clinician-rated HAM-D17 total score \<18 at both Screening and Baseline visits.
•CGI-Severity score ≥4 at both Screening and Baseline visits.
•Subject must have:
•* experienced and documented a minimum total of six social interaction or performance events during the two week Screening Period prior to the Baseline Visit, and
•* for at least three of these events, must have achieved a peak score of ≥60 on the Subjective Units of Distress Scales (SUDS), as rated in the Patient Diary.
+1 more criteria

Exclusion Criteria

•History of bipolar disorder (I or II), schizophrenia, schizoaffective disorder, psychosis, eating disorder, obsessive-compulsive disorder. Any other current Axis I disorder other than SAD which is the primary focus of treatment. Note that subjects with concurrent Generalized Anxiety Disorder (GAD) are eligible for the study provided that GAD is not the primary diagnosis.
•Subjects who meet criteria for substance abuse within the year prior to entry.
•Clinically significant nasal pathology or history of significant nasal trauma, nasal surgery, or nasal-septal perforation that may have damaged the nasal chemosensory epithelium.
•An acute or chronic condition, including an infectious illness, uncontrolled seasonal allergies at the time of the study, or significant nasal congestion that potentially could affect drug delivery to the nasal chemosensory epithelium.
•Two or more documented failed treatment trials with a registered medication approved for SAD during the previous six months, whereby a treatment trial is defined as a period of at least six (6) weeks (or longer as documented in package insert for a particular drug) during which the patient received an adequate dosage (defined as the treatment dose indicated in the package insert to obtain efficacy for that particular drug) of the medication.
•Use of any psychotropic medication within 30 days prior to study entry (other than eszopiclone, ramelteon, zaleplon, or zolpidem for insomnia as described in Section 3.3).
•Concomitant use of non-study anxiolytics such as benzodiazepines or beta blockers during the study and within 30 days prior to study entry.
•Concomitant use of any over-the-counter, prescription product, or herbal preparation for treatment of the symptoms of social anxiety during the study and within 30 days prior to study entry.
•Prior exposure to PH94B.
•Improvement of more than 20% in the LSAS score at Baseline relative to Screening.
+4 more criteria

Locations (1)

The Medical Research Network, LLC

New York, New York, United States

Key Dates

Start Date

March 1, 2014

Primary Completion Date

October 1, 2014

Completion Date

March 1, 2015

Last Updated

December 7, 2015

Enrollment

ACTUAL participants

Conditions

Social Anxiety Disorder

Interventions

PH94B

DRUG

Placebo

OTHER

ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence

NCT07456631

Social Anxiety Disorder (SAD)Oppositional Defiant Disorder

View study

RECRUITINGNA

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

NCT06661460

ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)Specific Phobia+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 7, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)

Inclusion Criteria

Exclusion Criteria

ACTsocially: The (Dis)Similarities of ACT for Changing Internalizing and Externalizing Symptomatology in Adolescence

Internet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders

Individual Factors of CBT Underlying Success

Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder

Application of Virtual Reality Technology to Treatment of Social Anxiety

Intervention Social Anxiety: Combining Parent-child Treatment